^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Conmana (icotinib)

i
Company:
Betta Pharma
Drug class:
EGFR inhibitor
Related drugs:
20d
Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs. (PubMed, BMC Pulm Med)
Pathological type, liver metastasis, brain metastasis, NSE, and CYFRA 21 - 1 were identified as independent risk factors for stage IV NSCLC patients treated with EGFR-TKIs, while chemotherapy and radiotherapy were determined to be independent protective factors. Taking icotinib or gefitinib, as opposed to osimertinib, was an independent risk factor for advanced NSCLC patients.
Retrospective data • Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5)
|
EGFR mutation
|
Tagrisso (osimertinib) • gefitinib • Conmana (icotinib)
24d
Long-term benefit of afatinib combined with bevacizumab in a lung adenocarcinoma patient with a novel rare EGFR Q787L mutation. (PubMed, Int Immunopharmacol)
Our findings suggest that the combination of afatinib and bevacizumab may offer long-term clinical benefits for LUAC patients harboring the novel and rare EGFR Q787L mutation. This case highlights a potential therapeutic strategy warranting further investigation in clinical studies.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Avastin (bevacizumab) • Gilotrif (afatinib) • Conmana (icotinib)
30d
Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients. (PubMed, BMC Cancer)
This study highlights the high prevalence and detrimental impact of muscle loss during EGFR-TKIs treatment.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MDM2 (E3 ubiquitin protein ligase)
|
EGFR mutation
|
Gilotrif (afatinib) • Conmana (icotinib)
1m
Real-world Study of Icotinib in EGFR Mutant Non-small Cell Lung Cancer Based on the Therapeutic Drug Monitoring (PubMed, Zhongguo Fei Ai Za Zhi)
Icotinib demonstrates good therapeutic effect and tolerable toxicity on the EGFR gene mutant NSCLC. There is a certain negative correlation between the plasma drug concentration of Icotinib and its efficacy, while there seems no significant correlation with safety.
Journal • Real-world evidence
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Conmana (icotinib)
2ms
Transformation from acquired EGFR 19del/C797S to EGFR 19del/T790M in an advanced non-small cell lung cancer patient: a case report and literature review. (PubMed, Anticancer Drugs)
Whether first-generation EGFR inhibitors (e.g. icotinib or gefitinib) can sustainably control EGFR-sensitive mutations/C797S NSCLC following third-generation EGFR inhibitor treatment remains insufficiently reported. Our case report discusses a female patient with advanced lung adenocarcinoma carrying an EGFR exon 19 E746_A750delELREA mutation who received almonertinib as first-line treatment and developed C797S resistance during therapy. The patient was subsequently treated with a double dose of icotinib for 8 months until disease progression occurred, along with the development of an EGFR exon 20 T790M point mutation and TP53 mutation. This case provides clinical evidence suggesting that first-generation EGFR-TKIs may be an effective treatment strategy for patients with acquired EGFR 19del/C797S resistance following EGFR TKI therapy.
Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
|
TP53 mutation • EGFR mutation • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR exon 20 mutation
|
gefitinib • Conmana (icotinib) • Ameile (aumolertinib)
2ms
First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis. (PubMed, Front Oncol)
The study encompassed the following 19 treatments: Chemotherapy; Afatinib; Afatinib + Cetuximab; Apatinib + Gefitinib; Befotertinib; Cetuximab + Chemotherapy; Erlotinib; Erlotinib + Bevacizumab; Erlotinib + Chemotherapy; Gefitinib; Gefitinib + Chemotherapy; Gefitinib + Olaparib; Icotinib; Icotinib + Chemotherapy; Lazertinib; Naquotinib; Osimertinib; Osimertinib + Bevacizumab; Osimertinib + Chemotherapy. However, due to the limitations in the number and quality of included studies, these conclusions await further validation through more high-quality research. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024562981, identifier CRD42024562981.
Retrospective data • Review • Journal • PARP Biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Avastin (bevacizumab) • Erbitux (cetuximab) • Lynparza (olaparib) • Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • AiTan (rivoceranib) • Conmana (icotinib) • Lazcluze (lazertinib) • Semena (befotertinib) • naquotinib (ASP8273)
2ms
An observational study on drug holidays during three years of adjuvant therapy with icotinib in patients with IA1-IB stage lung cancer with high-risk factors and positive minimal residual disease (MRD) (ChiCTR2400094179)
P=N/A, N=108, Recruiting, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital); The First Affiliated Hospital of Wannan Medical College (Yijishan Hospita
New trial
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Conmana (icotinib)
4ms
Wnt/β-Catenin Pathway-Mediated PD-L1 Overexpression Facilitates the Resistance of Non-Small Cell Lung Cancer Cells to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. (PubMed, Discov Med)
Activation of the Wnt/β-catenin pathway mediates the high expression of PD-L1 to promote the resistance of NSCLC cells to icotinib. Thus, targeted inhibition of PD-L1 expression is of benefit for the treatment of NSCLC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
|
PD-L1 overexpression
|
Conmana (icotinib) • foscenvivint (PRI724)
5ms
Risk of treatment-related toxicity from EGFR tyrosine kinase inhibitors: a systematic review and network meta-analysis of randomized clinical trials in EGFR-mutant non-small cell lung cancer. (PubMed, J Thorac Dis)
This review included 23 randomized clinical trials incorporating 7,006 patients and 11 treatments: erlotinib, gefitinib, icotinib, afatinib, dacomitinib, osimertinib, furmonertinib, aumolertinib, pemetrexed-free chemotherapy (PfCT), pemetrexed-based chemotherapy (PbCT) and placebo. Difference in safety between the third-generation EGFR-TKIs was also first investigated comprehensively. Furthermore, this review elaborated the varied predominate spectrum and ranked the toxicity of EGFR-TKIs for providing toxicity rationale for treatment decisions.
Clinical • Retrospective data • Review • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • pemetrexed • Conmana (icotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib) • Ivesa (firmonertinib)
5ms
Clinical Study on Adjuvant Targeted Therapy with EGFR Mutation after Surgery for Stage IA Non-small Cell Lung Cancer (ChiCTR2400089820)
P2, N=30, Not yet recruiting, Jining Medical University Affiliated Hospital; Jining Medical University Affiliated Hospital
New P2 trial • Surgery
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
Conmana (icotinib)
5ms
New P2 trial
|
EGFR mutation • EGFR L858R
|
Conmana (icotinib)
5ms
A prospective, single-arm phase II clinical study of neoadjuvant therapy with icotinib combined with bevacizumab in EGFR-mutant positive non-small cell lung cancer. (ChiCTR2400089589)
P2, N=40, Not yet recruiting, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.; Peking Union Medical College Hospital, Chinese Academy of Medical Science
New P2 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Avastin (bevacizumab) • Conmana (icotinib)
6ms
The colony-stimulating factor-1 receptor inhibitor edicotinib counteracts multidrug resistance in cancer cells by inhibiting ABCG2-mediated drug efflux. (PubMed, Biomed Pharmacother)
These results underscore an additional pharmacological benefit of edicotinib against ABCG2 activity, suggesting its potential incorporation into combination therapies for patients with ABCG2-overexpressing tumors. Further research is warranted to validate these findings and explore their clinical implications.
Journal
|
ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2)
|
ABCG2 expression
|
Conmana (icotinib)
6ms
P2 data • Journal • Circulating tumor DNA • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Conmana (icotinib)
6ms
CORIN: Icotinib for Completed Resected IB NSCLC With EGFR Mutation (clinicaltrials.gov)
P2, N=128, Completed, Sun Yat-sen University | Recruiting --> Completed
Trial completion
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Conmana (icotinib)
7ms
New P2 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion
|
gefitinib • Conmana (icotinib)
7ms
Design and activity evaluation of new EGFR tyrosine kinase inhibitors containing cyclic polyamines. (PubMed, Bioorg Med Chem Lett)
A series of derivatives of Erlotinib and Icotinib were developed by incorporating a macrocyclic polyamine into a quinazoline scaffold to enhance their inhibitory activity against drug-resistant cells. Compound b demonstrated slightly improved inhibition activity against PC-9 Del19/T790M/C797S (IC50 = 496.3 nM). This could provide some insights for optimizing EGFR inhibitors, particularly in the context of EGFR triple mutants.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 19 deletion • EGFR T790M • EGFR wild-type • EGFR C797S
|
erlotinib • Conmana (icotinib)
7ms
ICTAN: Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation (clinicaltrials.gov)
P3, N=251, Terminated, Sun Yat-sen University | Trial completion date: Jan 2023 --> Feb 2024 | Recruiting --> Terminated; Slow accural.
Trial completion date • Trial termination
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Conmana (icotinib)
7ms
Simultaneous determination of icotinib, osimertinib, aumolertinib, and anlotinib in human plasma for therapeutic drug monitoring by UPLC-MS/MS. (PubMed, J Pharm Biomed Anal)
Overall, the method proved to be sensitive, reliable, and straightforward, enabling successful simultaneous determination of blood concentrations of icotinib, osimertinib, aumolertinib, and anlotinib in patients. The validity of the method has been confirmed across various instruments.
Journal
|
FGFR (Fibroblast Growth Factor Receptor)
|
Tagrisso (osimertinib) • Focus V (anlotinib) • Conmana (icotinib) • Ameile (aumolertinib)
7ms
Cost-effectiveness of adjuvant icotinib versus chemotherapy for patients with stage II-IIIA EGFR-mutated non-small cell lung cancer in China. (PubMed, BMJ Open)
Compared with adjuvant chemotherapy, adjuvant icotinib may be a cost-effective treatment for resected stage II-IIIA EGFR-mutated NSCLC as the WTP threshold is set at $40 500 per QALY.
Clinical • Journal • HEOR • Cost-effectiveness • Cost effectiveness
|
EGFR (Epidermal growth factor receptor)
|
Conmana (icotinib)
7ms
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer (clinicaltrials.gov)
P2, N=30, Active, not recruiting, Betta Pharmaceuticals Co., Ltd. | Trial primary completion date: Dec 2023 --> Dec 2024 | Recruiting --> Active, not recruiting
Enrollment closed • Trial primary completion date • Metastases
|
Conmana (icotinib) • Semena (befotertinib)
7ms
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC (clinicaltrials.gov)
P2/3, N=362, Active, not recruiting, Betta Pharmaceuticals Co., Ltd. | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date • Metastases
|
Conmana (icotinib) • Semena (befotertinib)
7ms
Journal
|
EGFR (Epidermal growth factor receptor)
|
Conmana (icotinib) • Semena (befotertinib)
8ms
New P2 trial • Metastases
|
Conmana (icotinib) • Semena (befotertinib)
9ms
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor for lung adenosquamous cell carcinoma harboring EGFR mutation: a retrospective study and pooled analysis. (PubMed, Front Oncol)
Erlotinib or gefitinib-treated patients had an overall survival trend that was superior to that of icotinib-treated patients. ASC harboring EGFR mutations can be treated with EGFR-TKI in a similar manner to Adenocarcinoma (ADC) harboring EGFR mutations. There is still a need for further investigation to identify the separate roles of ASC's two components in treating EGFR.
Retrospective data • Journal
|
EGFR (Epidermal growth factor receptor)
|
erlotinib • gefitinib • Conmana (icotinib)
9ms
Dacomitinib overcomes acquired resistance to osimertinib in advanced NSCLC patients with EGFR L718Q mutation: A two-case report. (PubMed, Medicine (Baltimore))
Dacomitinib is a potential treatment option for NSCLC patients with EGFR L718Q mutation after resistance to Osimertinib. Further research is needed to validate the efficacy of Dacomitinib in this context.
Preclinical • Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
Tagrisso (osimertinib) • gefitinib • Conmana (icotinib) • Vizimpro (dacomitinib)
10ms
Icotinib in a lung adenocarcinoma patient with acquired EGFR 19del/C797S mutation-mediated resistance to osimertinib: a case report. (PubMed, Anticancer Drugs)
The patient was then treated with icotinib for 8 months until the disease progressed. Icotinib may be effective in patients with the EGFR 19del-C797S resistant mutation acquired after osimertinib treatment.
Journal
|
EGFR (Epidermal growth factor receptor)
|
Tagrisso (osimertinib) • Conmana (icotinib)
11ms
Prognostic value of skeletal muscle measured by CT at the T4 level in advanced EGFR-positive non-small cell lung cancer patients treated with ecotinib (PubMed, Zhonghua Yi Xue Za Zhi)
DCA demonstrated good clinical prediction effectiveness of the nomogram. Low T4-SMD is a prognostic risk factor for patients with advanced EGFR-positive NSCLC receiving icotinib therapy.
Retrospective data • Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR positive
|
Conmana (icotinib)
1year
Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer. (PubMed, Heliyon)
In first-generation EGFR-TKIs treatment, gefitinib showed favorable efficacy compared to icotinib and erlotinib, particularly in patients with EGFR L858R mutations...In third-line treatments, the combination of osimertinib and anlotinib demonstrated superior efficacy compared to other regimens. Glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) mutation was an independent risk indicator of shorter OS following third-line treatments. Comprehending the tumor evolution in NSCLC is advantageous for assessing the efficacy and prognosis at each stage of treatment, providing valuable insights to guide personalized treatment decisions for patients.
Journal
|
POLE (DNA Polymerase Epsilon) • IKZF1 (IKAROS Family Zinc Finger 1) • RBM10 (RNA Binding Motif Protein 10) • RAC1 (Rac Family Small GTPase 1) • EPHA3 (EPH receptor A3) • RAD21 (RAD21 Cohesin Complex Component) • GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • PAK1 (p21 (RAC1) activated kinase 1) • PAK5 (P21 (RAC1) Activated Kinase 5)
|
EGFR mutation • EGFR L858R • GRIN2A mutation • RBM10 mutation
|
Tagrisso (osimertinib) • erlotinib • gefitinib • Focus V (anlotinib) • Conmana (icotinib)
1year
Complete pathologic response to neoadjuvant icotinib in stage IIIA EGFR-mutant lung adenosquamous carcinoma: A case report. (PubMed, Medicine (Baltimore))
Our case indicated that the feasibility of neoadjuvant icotinib in EGFR-mutant lung adenosquamous carcinoma.
Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR E746
|
Conmana (icotinib)
over1year
Clinical analysis of lung adenocarcinoma with epidermal growth factor receptor mutation transformed into sarcoma (PubMed, Zhonghua Jie He He Hu Xi Za Zhi)
We reported a patient with lung adenocarcinoma who developed EGFR-T790M mutation after first-line treatment with icotinib and sarcoma transformation after second-line treatment with almonertinib. Sarcoma transformation can be one of the forms of drug resistance in patients with lung adenocarcinoma with EGFR-TKIs. The prognosis of patients with adenocarcinoma after transformation into sarcoma is poor.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • EGFR T790M • ALK mutation • ROS1 mutation
|
Conmana (icotinib) • Ameile (aumolertinib)
over1year
New P2 trial • Combination therapy • Metastases
|
gemcitabine • Loqtorzi (toripalimab-tpzi) • Conmana (icotinib) • pimicotinib (ABSK021)
over1year
China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage Ⅳ non-small cell lung cancer (version 2023) (PubMed, Zhonghua Yi Xue Za Zhi)
As of August 23, 2023, the first generation EGFR-TKIs, gefitinib, icotinib, and erlotinib; the second generation EGFR-TKIs, afatinib and dacomitinib; and the third generation EGFR-TKIs, osimertinib, almonertinib, furmonertinib and befotertinib were all approved for marketing by China National Medical Products Administration (NMPA). In addition, multiple domestic third-generation EGFR-TKIs are undergoing clinical trials, such as rezivertinib (BPI-7711), limertinib (ASK120067), and oritinib (SH-1028). Meanwhile, mobocertinib and sunvozertinib, which targets EGFR 20ins mutations, were also approved by NMPA. With the increasing variety of EGFR-TKIs approved for marketing subsequently, it brings confusion to clinicians when choosing specific medications, and there is an urgent need to develop relevant treatment guidelines. Hence, the Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care and the Chinese Association for Clinical Oncologists convened experts to integrate the research results of various EGFR-TKIs, and proposed the "China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage Ⅳ non-small cell lung cancer (version 2023)", to provide reference for better clinical practice.
Clinical guideline • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • Conmana (icotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib) • Ivesa (firmonertinib) • Exkivity (mobocertinib) • Semena (befotertinib) • sunvozertinib (DZD9008) • Rui Bi Da (rezivertinib) • Sanrisso (rilertinib) • limertinib (ASK120067)
over1year
A fully validated method for simultaneous determination of icotinib, osimertinib, gefitinib and O-desmethyl gefitinib in human plasma using UPLC-MS/MS for therapeutic drug monitoring. (PubMed, J Pharm Biomed Anal)
The proposed method was used in 100 patients with non-small cell lung cancer for monitoring plasma concentration of the mentioned EGFR-TKIs. The trough concentrations of ICO were distributed between 226.42 ng/mL and 3853.36 ng/mL, peak concentrations were between 609.20 ng/mL and 2191.54 ng/mL. The trough concentrations of OSI were distributed between 110.48 ng/mL and 1183.13 ng/mL. The trough concentrations of GEF were distributed between 117.71 ng/mL and 582.74 ng/mL, while DeGEF was distributed from 76.21 ng/mL to 1939.83 ng/mL with two less than 20 ng/mL. The results of therapeutic drug monitoring aimed to investigate exposure-efficacy/toxicity relationship and improve the efficacy and safety of targeted therapies.
Journal
|
Tagrisso (osimertinib) • gefitinib • Conmana (icotinib)
over1year
A meta-analysis for the efficacy and safety of icotinib combined with radiotherapy in treating brain metastases of non-small cell lung cancer. (PubMed, Medicine (Baltimore))
Icotinib combined with radiotherapy can significantly short-term and long-term efficacy of NSCLC patients with brain metastases but not increase adverse reactions.
Retrospective data • Journal
|
Conmana (icotinib)
over1year
Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study). (PubMed, ESMO Open)
Two-year adjuvant icotinib was shown to significantly improve DFS and provide an OS benefit in EGFR-mutant, stage II-IIIA lung adenocarcinoma patients compared with 1-year treatment in this exploratory phase II study.
P2 data • Journal
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR positive
|
Conmana (icotinib)
over1year
Optimizing the Treatment for Advanced Non-Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review. (PubMed, J Immunother Precis Oncol)
The results were similar when erlotinib or icotinib was compared with gefitinib. Progression-free survival and overall survival for afatinib and dacomitinib were longer than for gefitinib, with small significant differences...Osimertinib is the preferred first-line treatment in patients with advanced EGFR-mutated NSCLC. First- and second-generation TKIs are still considered good options, especially in low-income countries that cannot cover the costs of osimertinib.
Review • Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR T790M
|
Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib • Conmana (icotinib) • Vizimpro (dacomitinib)
over1year
Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States. (PubMed, Pharmacol Res)
Although the efficacy of imatinib in the treatment of chronic myelogenous leukemia in the United States in 2001 was the main driver of protein kinase inhibitor drug discovery, this was preceded by the approval of fasudil (a ROCK antagonist) in Japan in 1995 for the treatment of cerebral vasospasm...One-third of the 21 internationally approved drugs are not compliant with Lipinski's rule of five for orally bioavailable drugs. The rule of five relies on four parameters including molecular weight, number of hydrogen bond donors and acceptors, and the Log of the partition coefficient.
Review • Journal
|
EGFR (Epidermal growth factor receptor)
|
imatinib • Focus V (anlotinib) • AiTan (rivoceranib) • Irene (pyrotinib) • Conmana (icotinib) • Velexbru (tirabrutinib)
over1year
UPDATED EFFICACY AND SAFETY PROFILE OF PIMICOTINIB (ABSK021) IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): 1-YEAR FOLLOW-UP FROM PHASE 1B (CTOS 2023)
With the extension of treatment duration, there is an observed augmentation in the number of pts experiencing sustained tumor shrinkage and favorable safety of Pimicotinib with no apparent hepatotoxicity. Current data confers durable therapeutic benefits in TGCT pts, suggesting that prolonged exposure may represent an optimal treatment approach. In addition, a separate cohort with prior anti-CSF-1/CSF-1R therapies is underway to assess the safety and antitumor activity.
Clinical • P1 data
|
CSF1R (Colony stimulating factor 1 receptor)
|
CSF1R overexpression
|
Conmana (icotinib) • pimicotinib (ABSK021)
over1year
Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study. (PubMed, Mol Cancer)
Anlotinib combined with icotinib was effective and well-tolerated as a first-line treatment option for EGFR mutation-positive advanced NSCLC with or without concurrent mutations.
P2 data • Clinical Trial,Phase II • Journal • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Focus V (anlotinib) • Conmana (icotinib)
over1year
Clinical efficacy and safety of adjuvant EGFR-TKIs for resected stage IB lung adenocarcinoma: A real-world study based on propensity score matching. (PubMed, Cancer Med)
Adjuvant EGFR-TKIs could significantly improve DFS among patients with stage IB lung adenocarcinoma compared with CO, with a safe and tolerable profile.
Journal • Real-world evidence • Real-world
|
Tagrisso (osimertinib) • gefitinib • Conmana (icotinib)
over1year
Treatment Patterns and Clinical Outcomes among Advanced NSCLC Patients with EGFR exon 20 Insertion Mutations in China (IASLC-WCLC 2023)
Among these 59 patients, eight (13.6%) received EGFR TKIs (e.g., afatinib, icotinib, and osimertinib), two patients (3.4%) received IO therapy, eleven (18.6%) initiated platinum-based chemotherapy, fourteen (23.7%) received docetaxel, ten (16.9%) bevacizumab, five (8.5%) paclitaxel, and ten (16.9%) other chemotherapy in the 2nd LOT. The prognosis of advanced NSCLC patients with EGFR ex20ins in China was sub-optimal. The results of this study suggested there is an unmet need of novel therapy for these patients in China.Demographics, treatment patterns, and clinical outcomes of advanced NSCLC patients in ChinaTotal (N=116)Site, %Shanghai60.3Beijing39.7Age, yearMean56.2Median57.6Range27.8 - 76.1Insurance type, %Urban medical59.5Rural medical9.5Smoking status, %Current18.1Previous13.8Non-smoker62.1Cancer stage, %IIIb3.5IVa53.5IVb37.9Not specified5.2Tested for PD-L1, %Positive5.7Negative3.5Unknown74.1Patients with LOTs, %1st LOT1002nd LOT57.8Post-platinum 2nd LOT50.91st LOT (N=116), %Platinum-based chemotherapy85.3EGFR TKI2.6Immunotherapy0.9Other11.22nd LOT (N=59), %Platinum-based chemotherapy18.6EGFR TKI13.6Immunotherapy3.4Other64.4PFS of 1st LOTPFS, median (95% CI)6.2 (5.6, 8.0)Censored, %37.9PFS of post-platinum 2nd LOTPFS, median (95% CI)4.2 (2.7, 5.1)Censored, %25.4Confirmed ORR, %1st LOT14.8Post-platinum 2nd LOT10.0
Clinical • Clinical data • PD(L)-1 Biomarker • IO biomarker • EGFR exon 20 • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
Avastin (bevacizumab) • Tagrisso (osimertinib) • Gilotrif (afatinib) • paclitaxel • docetaxel • Conmana (icotinib)